Skip to main content
Manish Shah, MD, Oncology, New York, NY, New York-Presbyterian Hospital

ManishAShahMD

Oncology • New York, NY

Gastrointestinal Cancer, Hematologic Oncology

Chief Solid Tumor Oncology Service, Bartlett Family Professor of Medicine, Weill Cornell Medicine, Director, Gastrointestinal Oncology Program, co-Director, Center for Advanced Digestive Care, NewYork-Presbyterian

Request Appointment

Overview of Dr. Shah

Dr. Manish Shah is an oncologist in New York, NY and is affiliated with NewYork-Presbyterian/Weill Cornell, and New York-Presbyterian Hospital. He received his medical degree from Harvard Medical School and has been in practice 21 years. He specializes in gastrointestinal oncology and drug development. Dr. Shah is Chief of the Solid Tumor Service and co-Director for the Center for Advanced Digestive Care at New York-Presbyterian.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2001
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1996 - 1999
  • Harvard Medical School
    Harvard Medical SchoolClass of 1996
  • Johns Hopkins University
    Johns Hopkins UniversityB.E.S., 1987 - 1991

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2022 - 2025
  • NY State Medical License
    NY State Medical License 1999 - 2024
  • NC State Medical License
    NC State Medical License 1997 - 2000
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Department of Medicine Young Investigators Award 2014
  • Donald L. Morton Award Journal for Surgical Oncology, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction  
    Bartley AN, Christ J, Fitzgibbons PL, et al, Archives of pathology & laboratory medicine, 10/2/2014
  • The role of (1)(8)F-FDG PET imaging in upper gastrointestinal malignancies  
    Dai T, Popa E, Shah MA, Current treatment options in oncology, 9/1/2014
  • Is gastric cancer different in Korea and the United States? Impact of tumor location on prognosis  
    Shim JH, Song KY, Jeon HM, Park CH, Jacks LM, Gonen M, Shah MA, Brennan MF, Coit DG, Strong VE, Ann Surg Oncol, 7/1/2014
  • Join now to see all

Books/Book Chapters

  • Textbook of Uncommon Cancer. 
    Chapter: Uncommon Cancers of the Stomach. 
    Popa E, Schnoll-Sussman F, Jesudian A, Nandakumar G, and Shah MAEditors: Raghavan, Blanke.Wiley-BlackwellEdition 4th,2012
  • 100 Questions about Gastric Cancer. 
    Shah MA, Pinheiro NP, Shah BM (Eds)Editors: Shah MA, Pinheiro NP, Shah BM (Eds).Jones and Bartlett, Sudbury, MA2008
  • Molecular Basis of Cancer. 
    Chapter: The Molecular Basis of Gastric and Gastroesophageal Adenocarcinoma. 
    Page 511 - 520Shah MA and Kelsen DPEditors: Mendelsohn, Howley, Thompson, Grey, and Israel.Saunders Elsevier, Philadelphia, PA2008
  • Join now to see all

Abstracts/Posters

  • Cancers of the Esophagus and Stomach.
    Shah MA, Gastrointestinal Cancers Symposium, San Francisco, CA, 1/16/2014
  • Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients with advanced gastric ca...
    Shah MA, Gastrointestinal Cancers Symposium, San Francisco, CA, 1/19/2012
  • Phase II study of preoperative chemotherapy with irinotecan and cisplatin for gastric cancer (NCI 5917): FDG PET/CT predicts patient outcome.
    Shah MA, ASCO, 6/3/2007

Lectures

  • Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: Phase 2 KEYNOTE-180 study. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
  • Targeted therapies in gastric cancer. 
    Madrid, Spain - 6/26/2014
  • Join now to see all

Other

  • Cancer of the stomach. 
    Shah M, Strong V
    1/1/2009
  • The function of neuron specific kinesin heavy chain as assessed by antisense technology. 
    Manish A. Shah, Publ Harvard Medical School, Thesis
    2/1/1996

Press Mentions

  • Zolbetuximab Improves Survival in Gastric Cancer
    Zolbetuximab Improves Survival in Gastric CancerMarch 26th, 2023
  • Astellas Announces Positive Findings from Phase 3 GLOW Trial of … – PR Newswire
    Astellas Announces Positive Findings from Phase 3 GLOW Trial of … – PR NewswireMarch 21st, 2023
  • Major Immune Cells Maintain Healthy Gut Bacteria to Protect Against Colorectal Cancer
    Major Immune Cells Maintain Healthy Gut Bacteria to Protect Against Colorectal CancerAugust 31st, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    BCBS Illinois PPO
    BCBS Minnesota Blue Cross Accord
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    First Choice
    First Health PPO
    GHI PPO
    Great West PPO
    Health Alliance PPO
    Health Net Oregon PPO
    Healthfirst New York
    HIP of New York - Select PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    ODS Network
    Oxford Health Freedom
    Oxford Health Liberty
    Premera BCBS Heritage & Heritage Plus 1
    Providence Health System Personal Option
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
    Wellmark Alliance Select
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Manish Shah, Dr. Manish Shah, MD, Dr. M Shah, Dr. Manish A Shah